Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arrowhead Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback